Biden names Ozempic, Wegovy for price negotiation program
The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the second...
CMS proposes increasing Medicare Advantage benchmark payments by 2.2%, or $21 billion
Medicare Advantage benchmark payments are poised to increase by 2.23%, the Centers for Medicare & Medicaid Services proposed in a...
23.6M have signed up for ACA plans during open enrollment: CMS
More than 23 million people have selected coverage on the Affordable Care Act’s exchange as part of open enrollment, according...
HHS releases cost savings for 64 prescription drugs
The Centers for Medicare and Medicaid Services announced Friday that 64 Part B drugs will have a reduced price for...
SCOTUS upholds Arkansas’ 340B drug pricing law
The U.S. Supreme Court refused to hear an appeal by a pharmaceutical industry group challenging Arkansas’ 340B drug pricing law....
Future White House AI Czar Sacks likely to favor startups
Donald Trump has announced his intention to appoint venture capitalist and lawyer David O. Sacks to be “White House A.I....
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model
Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it...
Staffers predict future of AI amidst D.C. leadership change
Health policy staffers gathered last week at the Capitol for a day of discussing AI policy with members of industry,...
Trump could boost Medicare Advantage—but reform may be coming
Medicare Advantage (MA) insurer stocks soared following Election Day, with healthcare onlookers assuming the new Trump administration would set favorable...
4M could become uninsured if enhanced ACA subsidies end
Should policymakers choose not to extend enhanced subsidies for Affordable Care Act (ACA) plans, about 4 million people would likely...
